The global anticoagulants reversal drugs market expected to expand at a CAGR of 15.3% from 2018 to 2026. The global anticoagulants reversal drugs market expected to expand at a CAGR of 15.3% from 2018 to 2026.
Market Insights
The global anticoagulant reversal drugs market is poised to grow during the forecast period owing to approval of blockbuster drugs in the recent years and strong pipeline driving the market. The U.S. Food and Drug Administration has designated Andexxa (the most recent approved drug for factor Xa inhibitors) as orphan drug and tagged under accelerated approval process. European Medicines Agency is also positive to grant approval for andexanet alfa, with Committee for Medicinal Products for Human Use (CMPH) reviewing the application. Idarucizumab, approved in 2015 for antidote for dabigatran during atrial fibrillation, is currently under clinical trials for multiple conditions such as hemorrhage and stroke. Thus strong pipeline and governmental initiatives will drive the market for anticoagulant reversal drugs market. Drugs type such as prothrombin complex concentrates, Vitamin K, desmopressin which were earlier preferred for contain emergency situation will demonstrate sluggish growth due to launch of novel drugs with better efficacy and quicker effect. However, high prices of patented drugs would act as a growth barrier in emerging economies.
In terms of geography, North America held the largest share in the global anticoagulant reversal drugs market owing to increased approvals and increasing research and development by major pharmaceutical companies in the region. Europe also a held a significant share in the global market attributable to product approvals. Growing incidence of uncontrollable bleeding episodes and usage of anticoagulants will further drive the market in the North America and Europe. U.S. emerged as the largest country level market due to efficient reimbursement scenario of for drugs, high cost of the recently approved drugs and accelerated drug approval initiative by U.S. Food and Drug Administration (FDA) to drive the market. Asia Pacific is set to grow at fastest rate during the forecast period, driven by rising patient population for diseases such as atrial fibrillation, strokes and other cardiopulmonary diseases. Ongoing trials in the region will further stimulate the market growth in the region. The key players currently engaged in anticoagulant reversal drugs market include Boehringer Ingelheim GmbH, Fresenius Kabi AG, Bausch Health Companies, Inc., CSL Behring Limited, Octapharma AG, Portola Pharmaceuticals, Inc., Perosphere Pharmaceuticals, Inc. and Ferring Pharmaceuticals.
Key Market Movements:
- Strong pipeline for anticoagulant reversal drugs in North America and Europe to drive the market during the forecast period
- Growing research and development by pharmaceutical players further boost market growth
- Rising incidence of uncontrollable bleeding episodes and emergency situation due to use of anticoagulants
Frequently asked questions about global industry
- Which are the different Application Industries of this market?
Ans: Electronics, Food, and Others are the different end-use industries available in the market - Name few prominent players in the global industry.
Ans: Linde, Praxair, Dongyue Group, Beifang TeQi, Matheson, Airgas, and Juhua Group are the key players operating in this market - Which is the fastest growing Application segment for global industry?
Ans: Semiconductor Devices have high application - Which is the leading regional market for global industry?
Ans: Asia-Pacific has the largest share owing to various developments happening in this space - What will be the CAGR (2021 - 2027) of in global industry?
Ans: The market is anticipated to grow at a CAGR of 12.1% throughout the forecast period
Browse the full report at https://www.credenceresearch.com/report/anticoagulant-reversal-drugs-market
ToC:
Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I – Secondary Research
1.3.2. Phase II – Primary Research
1.3.3. Phase III – Expert Panel Review
1.3.4. Assumptions
1.4. Market Segmentation
Chapter 2. Executive Summary
2.1. Global ARD Market Portraiture
2.2. Global ARD Market, by Drug Class, 2017 (US$ Mn)
2.3. Global ARD Market, by Geography, 2017 (US$ Mn)
Chapter 3. Anticoagulant Reversal Drugs (ARD): Market Dynamics and Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2017
3.6. Competitive Analysis: Global ARD Market, by Key Players, 2017
Chapter 4. Global Anticoagulant Reversal Drugs (ARD) Market, by Drug Class, 2016-2026 (US$ Mn)
4.1. Overview
4.2. Prothrombin Complex Concentrates (PCC)
4.3. Vitamin K
4.4. Protamine
4.5. Tranexmic Acid
4.6. Desmopressin
4.7. Idarucizumab
4.8. Andexxa
4.9. Pipeline Analysis
4.9.1. Phase III Drugs
4.9.1.1. Octaplex
4.9.2. Phase I and II Drugs (Tabular Representation)
Chapter 5. Global Anticoagulant Reversal Drugs (ARD) Market, by Geography, 2016 – 2026 (US$ Mn)
5.1. North America ARD Market Analysis, 2016 – 2026
5.1.1. North America ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.1.2. North America ARD Market, by Country, 2016 – 2026 (US$ Mn)
5.1.2.1. U.S.
5.1.2.2. Canada
5.2. Europe ARD Market Analysis, 2016 – 2026
5.2.1. Europe ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.2.2. Europe ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.2.2.1. U.K.
5.2.2.2. Germany
5.2.2.3. Rest of Europe
5.3. Asia Pacific ARD Market Analysis, 2016 – 2026
5.3.1. Asia Pacific ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.3.2. Asia Pacific ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.3.2.1. China
5.3.2.2. Japan
5.3.2.3. Rest of Asia Pacific
5.4. Latin America ARD Market Analysis, 2016 – 2026
5.4.1. Latin America ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.4.2. Latin America ARD Market, by Country/Region, 2016 – 2026 (US$ Mn)
5.4.2.1. Brazil
5.4.2.2. Mexico
5.4.2.3. Rest of Latin America
5.5. Middle East & Africa ARD Market, 2016 – 2026
5.5.1. Middle East & Africa ARD Market, by Drug Class, 2016 - 2026 (US$ Mn)
5.5.2. Middle East & Africa ARD Market, by Region, 2016 – 2026 (US$ Mn)
5.5.2.1. GCC
5.5.2.2. Rest of Middle East & Africa
Chapter 6. Company Profiles
6.1. Boehringer Ingelheim GmbH
6.1.1. Business Description
6.1.2. Financial Information (Subject to Data Availability)
6.1.3. Product Portfolio
6.1.4. News Coverage
6.2. Fresenius Kabi AG
6.3. Pfizer, Inc.
6.4. Bausch Health Companies, Inc.
6.5. Amneal Pharmaceuticals, Inc.
6.6. CSL Behring Limited
6.7. Octapharma AG
6.8. Portola Pharmaceuticals, Inc.
6.9. Perosphere Pharmaceuticals, Inc.
6.10. Ferring Pharmaceuticals
Browse the full report at https://www.credenceresearch.com/report/anticoagulant-reversal-drugs-market
Related Reports:
Octafluorocyclobutane Market by End-use Industry (Food, Electronics, Others) by Application (Semiconductor Devices, Refrigerant, Others): Growth, Future Prospects & Competitive Analysis, 2015 - 2027
Thanks for reading this article ; you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.
About Us
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives.
Media Contact
Company Name: Credence Research
Contact Person: Chris Smith
Email: Send Email
Phone: 18003618290
City: SAN JOSE
State: CA
Country: United States
Website: https://www.credenceresearch.com/report/anticoagulant-reversal-drugs-market
